A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • Events
  • Lecture: Utrecht University: Sustainability, Health &...
Lecture - Event date: 24 Sep 2020

Utrecht University: Sustainability, Health & Innovation

On September 24, Fatema Rafiqi, Research Programme Manager for the Access to Medicine Foundation, will join Utrecht University virtually for a series of guest lectures on Sustainability, Health & Innovation.

Fatema will participate in a series of digital guest lectures about challenges for the development and distribution of medicines in resource-restricted settings. The goal of Sustainability, Health & Innovation (SHI) is to teach students about issues related to the development and distribution of medical interventions for low- and middle-income countries (LMICs). 

In her virtual lecture, Fatema will discuss a number of topics, including:

  • Challenges for developing medicines in LMICs and directions for solutions
  • The work of the Access to Medicine Foundation, in particular the rationale for the Access to Medicine Index and the Antimicrobial Resistance Benchmark
  • A case study on tuberculosis 
  • Insights on the development and accessibility of prospective COVID-19 interventions in LMICs.

Other guest speakers from the following organisations will also join the lecture:

  • KNCV Tuberculosis Foundation
  • Lygature
  • Phasuma
  • Vereniging Innovatieve Geneesmiddelen (VIG)
  • Ministerie VWS
  • WEMOS

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |